Syntaxin is a biopharmaceutical company focusing on the discovery and development of new medicines derived from bacterial toxins to treat chronic diseases.
The company was founded in 2005 to develop complex proteins that can be used as biopharmaceuticals to treat neurological, inflammatory and endocrine diseases.
The Company's biopharma product pipeline is based on exploiting the potent pharmacological properties of some microbial proteins, notably exotoxins.
|
|